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Summary 
Mannose-binding protein (MBP), Clq, the recognition 
component of the classical complement pathway, and 
pulmonary surfactant protein A (SP-A) are members 
of a faniily of molecules containing a collagen-like se- 
quence contiguous with a noncollagen-like sequence, 
and usually having the properties of a lectin. Clq and 
SP-A have been shown to enhance monocyte FcR- and 
CRl-mediated phagocytosis, suggesting that thecom- 
mon structural features of the collagen-like domains 
may provide a basisforthis immunologically important 
function. Results presented here demonstrate that 
MBP also enhanced FcR-mediated phagocytosis by 
both monocytes and macrophages, and stimulated 
CRl-mediated phagocytosis in human culture-derived 
macrophages and in phorbol ester-activated mono- 
cytes. Furthermore, a monoclonal antibody that recog- 
nizes a 126,000 M, cell surface protein and inhibits 
Clq-enhanced phagocytosis, inhibited the MBP-medi- 
ated enhancement of phagocytosis. Thus, the recep- 
tors that mediate the enhancement of phagocytosis 
by MBP and Clq share at least one critical functional 
component, the 126,000 M, ClqRp. 
Introduction 
The human mannose-binding protein (MBP) represents a 
nonclonal form of humoral immunity in which discrimina- 
tion of self versus nonself relies on the recognition of car- 
bohydrate antigens that are common to pathogens but are 
rarely if ever expressed on host cell surfaces or circulating 
glycoproteins (reviewed by Ezekowitz, 1991). Mannose 
binding proteins have been isolated from serum and liver 
of man and rodents. The predominant circulating form of 
MBP appears as a multimer of approximately 600,000 Da 
of a 32,000 Da subunit. Examination of the sequence pre- 
dicted from rodent and human cDNAs reveals an NH2 
terminus containing cysteine residues, which may, via in- 
terchain disulfide bonds, stabilize a collagen helix com- 
prised of up to 19 repeats of Gly-X-Y in the contiguous 
amino acid sequence. The carboxy half of the MBP mole- 
cule constitutes a carbohydrate recognition domain (CRD) 
and has features of an ever-growing family of animal C-type 
lectins (Drickamer, 1987). 
The presence of a collagen-like domain in a nonmatrix 
polypeptide, while previously somewhat unusual, is now 
being discovered in an, as of yet, small family of proteins 
called collectins (Malhotra et al., 1992; Sastry and Ezeko- 
witz, 1993), which contain a region of collagen-like sequence 
(Gly-X-Y) contiguous with recognition domains composed 
of noncollagen-like amino acid sequences (Drickamer et 
al., 1966; Thiel and Reid, 1989), usually with lectin-like 
properties. In addition to MBP, the other members of this 
family are the pulmonary surfactant proteins, SP-A and 
SP-D (Shimizu et al., 1992), the classical complement 
component, Clq, and conglutinin, a protein that binds to 
the iC3b fragment of complement C3 (Lee et al., 1991; 
Lachmann, 1967). MBP, SP-A, and Clq all have an inter- 
ruption in the Gly-X-Y repeat pattern of the collagen-like 
sequence (Drickamer et al., 1988), hydroxylated amino 
acids, and short NH,-terminal domains containing in- 
terchain disulfide bonds. Electron microscopy has demon- 
strated remarkable similarity in macromolecular structure 
(Vosset al., 1988) between Clqand SP-A. With theexcep 
tion of the glycine residues in every third residue in the 
collagen-like domain, the proteins bear no common se- 
quence identity to one another. Interestingly, all of these 
molecules have been shown to enhance uptake of defined 
material (Friis-Christiansen et al., 1990; Krieger, 1992). 
SP-A enhances the uptake of lipids by isolated alveolar 
type II cells (Wright et al., 1987), while MBP augments the 
uptake by phagocytes of certain bacteria, viruses, and 
model polymers in vitro (Kuhlman et al., 1989; Hartshorn 
et al., 1993; Soell et al., 1995). It has been well docu- 
mented that Cl q has properties of both an opsonic ligand 
(mediating binding/recognition of microbes or model parti- 
cles by the cells) (Sorvillo et al., 1986) and an activation 
ligand (enhancing the response of the cell to the binding 
of a second ligand to a different receptor) (Bobak et al., 
1987, 1988; Brown, 1986). These effects were mediated 
via the collagen-like fragment of Clq, as the isolated pep- 
sin-resistant fragment, but not the pepsin-sensitive colla- 
genase-resistant fragments, was effective in enhancing 
phagocytic activity (Bobak et al., 1987). Tenner et al. 
(1989) previously showed that, like Clq, SP-A can en- 
hance FcR- and CR1 -mediated phagocytosis by mononu- 
clear phagocytes, suggesting that common structural fea- 
tures of the collagen-like domains may provide a basis for 
this biological function. A cellular protein that binds to the 
head regions of Clq has recently been described (Ghe- 
brehiwet et al., 1994). This indicates that Cl q can interact 
with cellsvia the collagen-like region (tail) and the globular 
heads. 
Mannose-binding protein is also a member of a family 
of proteins including the macrophage mannose receptor 
(MR) (Ezekowitz et al., 1990; Taylor et al., 1990), a lectin 
found in the abdominal cavity of the flesh fly Sarcophaga 
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and a recently described lipopolysaccharide-binding pro- 
tein from the hemolymph of the American cockroach, Peri- 
planeta americana, that have a role in host defense and 
are up-regulated in response to infection or trauma (Jomori 
and Natori, 1991; Ezekowitz et al., 1988; Taylor et al., 
1989). For example, stable accumulation of Sarcophaga 
lectin mRNA increases significantly in response to the in- 
troduction of foreign substances into the abdominal cavity 
of flesh flies (Takahashi et al., 1985). Similarly, the hepatic 
synthesis of the human mannose-binding protein as well 
as the mouse MBPA are up-regulated as part of the acute 
phase response (Sastry et al., 1991). These similarities 
between the regulation of the mammalian proteins and 
those found in insects suggest that the role of the man- 
nose-binding protein in host defense has primitive origins. 
The results of experiments described here demonstrate 
that MBP, like Clq and SP-A, is an activation ligand as well 
as an opsonic ligand. Furthermore, a monoclonal antibody 
(MAb) that recognizes a component of the Clq receptor 
on myeloid cells that enhances phagocytic activity (Cl qRp) 
inhibits the MBP-mediated increase in phagocytosis, sug- 
gesting that the receptor for these two ligands share at 
least one polypeptide component. This mechanism of acti- 
vation may be relevant at sites of inflammation where 
these molecules can accumulate, and could provide a 
beneficial enhancement of the phagocytic capacity of 
acute inflammatory cells. Finally, competitive binding 
studies demonstrate that Clq and MBP share an interac- 
tion site on human myeloid cells, lending support to the 
hypothesis that the similar collagen-like macromolecular 
structure may mediate a similar function. These ligands 
may be examples of elements of innate immunity that can 
function both as a first line of defense prior to production 
of specific antibody and synergistically with the adaptive 
immune system in protecting the host from infection. 
Results 
MBP Enhances FcR-Mediated Phagocytosis 
The collagen-like region of Clq, SP-A, and collagen type 
IV, but not collagen type I, have been shown to increase 
the phagocytosis of opsonized particles by mononuclear 
phagocytes(Bobaket al., 1987; Tenner et al., 1989; Brown 
and Goodwin, 1988). MBP, an acute phase response pro- 
tein, has been shown to act directly as an opsonin of man- 
nose-rich pathogens. Given the similarity of macromolecu- 
lar structure of MBP with Clq and SP-A, we investigated 
whether MBP could, like Cl q and SP-A, activate the mono- 
nuclear cell in such a way as to increase the subsequent 
phagocytosis of particles opsonized with IgG. Multivalent 
presentation of Clq or a conformational change induced 
by aggregation or immobilization of the Clq monomer 
seems to be required for the generation of a functional 
response upon binding to cells (Tenner and Cooper, 1982). 
This requirement is similar to that seen with CRl, CR2, 
FcRII, FcRIII, and many other surface receptors (Wener 
et al., 1989; Brunswick et al., 1989). Therefore, human 
monocytes were added to glass slides previously coated 
with either Clq, MBP, or serum albumin to which the cells 
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Figure 1. MBP Enhances Monocyte F&Mediated Phagocytosis 
Human monocytes purified by countercurrent elutriation were added 
to LabTek chambers that had been precoaled with 4, 6, or 16 uglml 
of HSA (inverted closed triangle), Clq (closed circle), or rMEP (open 
inverted triangle). EAlpG targets were added and phagocytosis was 
assessed. 
(A) The percentage of monocytes ingesting at least one & target. 
(B) The number of targets ingested per 100 monocytes. Values pre- 
sented are the mean + SD of duplicate samples from one of six similar 
experiments. 
adhered. After 1 hr, immunoglobulin G (IgG)-coated tar- 
gets were added and incubated for 30 min at 37%. Figure 
1 presents the data from 1 of 6 separate experiments dem- 
onstrating that mannose-binding protein enhances FcR- 
mediated phagocytosis in a dose-dependent manner as 
compared with cells adherent to uncoated surfaces. This 
increase was seen both as an increase in the percentage 
of cells ingesting the target particles (Figure 1A) and as 
an increase in the number of targets ingested per cell 
(Figure 1 B, phagocytic index). Phagocytosis of unopso- 
nized erythrocytes is never seen under any condition 
tested. 
This ability to function as an activation ligand was not 
specific for freshly isolated monocytes. In vitro culture con- 
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ditions are known to influence macrophage differentiation 
(Bobak et al., 1988; Wright and Silverstein, 1982). Isolated 
human monocytes cultured in a defined serum-free me- 
dium, HL-1, have less of the characteristics of macro- 
phages than do those cultured for the same period of time 
in media containing 10% fetal calf serum (FCS) (Bobak 
et al., 1988). However, MBP was found to enhance the 
ingestion of IgG-coated E, by phagocytes previously cul- 
tured for 3-7 days with either HL-1 or in media containing 
10% FCS. In three separate experiments, MBP increased 
EAIgG phagocytosis 3- to 4-fold more than cells adhered 
to control surfaces. This degree of enhancement was simi- 
lar to that seen with Clq, and comparable also to that 
previously published for SP-A (Tenner et al., 1989). Fur- 
thermore, results were similar whether native MBP or re- 
combinant MBP was presented to the cells (data not 
shown). 
CR-l-Mediated Phagocytosis Is Modulated by MBP 
To determine whether this stimulation of the phagocytic 
capacity of monocyteslmacrophages was specific only for 
targetsengaging the FcR, we tested whethertargets opso- 
nized with IgM and C4b that bind to the C3b receptor, CR1 
(Bohnsack et al., 1985) were also ingested to a greater 
degree upon interaction of the phagocytes with MBP. 
While monocytes readily bind and ingest IgG-opsonized 
particles and avidly bind CBb-/C4b-coated particles, these 
“resting” phagocytes do not ingest particles bound via 
CR1 , unless activated to become macrophages or treated 
with tumor-promoting phorbol esters, such as PDBu (Bo- 
bak et al., 1988). Thus freshly isolated monocytes were 
added to wells coated with MBP, Clq, or control proteins, 
or treated with buffer only. After 1 hr at 37% EAI,&4b 
targets were added to the wells in the presence of 10 nglml 
PDBu. While the absolute amount of phagocytosis varied 
among the experiments (n = 6) MBP (recombinant or 
native) consistently augmented CRl-mediated phagocy- 
tosis to roughly the same degree as Cl q. Table 1 presents 
results from several experiments in which a coating solu- 
tion of 8-10 pglml of the test protein was used. MBP, 
like Clq, increased both the percentage of cells ingesting 
targets (1.8-to 8.1 -fold) and the number of targets ingested 
per effector cell scored (1.9- to 13.9-fold increase) relative 
to human serum albumin (HSA) or bovine serum albumin 
(BSA) control or uncoated control wells (Table 1). 
MAb against ClqRp Inhibits MBP-Mediated 
Enhancement of Phagocytosis 
To determine whether the monocyte receptors for Clq 
and MBP that increase the phagocytic response contain a 
common receptor component, the MAb, R139, that inhibits 
the Clq-mediated enhancement of phagocytosis was 
tested for its effect on the MBP-induced increase in phago- 
cytosis. EA,,&4b targets, rather than EAIO~, were used in 
these experiments to avoid potential competition with FcR. 
Purified monocytes were preincubated with either buffer, 
R139 (anti-ClqRp) or a control MAb for 15 min prior to 
addition to HSA-, Clq-, MBP-, or fibronectin-coated wells. 
R139 inhibited both the Clq- and the MBP-mediated en- 
hancement of phagocytosis but did not effect the fibronec- 
tin-induced increase in phagocytosis (Figure 2). As has 
been seen previously (Guan et al., 1991, 1994) the inhibi- 
tion of number of targets ingested per cell was more pro- 
nounced (59%-820/o inhibition) (n = 3, p < .OOl) than 
the percentage of cells actively engaged in phagocytosis 
(370/o-81% inhibition) (n = 3, p < ,003). Knowledge of the 
signal transduction mechanisms should provide insights 
into the basis for these differential inhibitory effects. 
Effect of MBP on the Binding of Clq to Monocytes, 
U937 Cells, and Neutrophils 
Since both MBP and Clq triggered a similar enhancement 
of phagocytosis and this was inhibited by the MAb to a 
126,000 M, cell surface protein, it was possible that these 
ligands were interacting with the same cell surface recep- 
tor. If so, MBP should be able to compete effectively with 
Clq for binding to these cells. Therefore, the ability of 
MBP to inhibit the binding of 1251-C1q-(collagen-like frag- 
ment)CLF was assessed. Figure 3 presents binding data 
from several experiments that demonstrate that MBP re- 
producibly inhibited the binding of Clq-CLF to monocytes 
by 25%. Similarly, binding to neutrophils (Figure 4) and 
U937 (data not shown) was also inhibited by 25%-420/o. In 
control experiments, mannan, which would competitively 
block the MBP lectin domain, had no effect on the ability 
of MBP to inhibit ‘251-C1q-CLF on monocytes. That is, in 
two additional experiments MBP inhibited Clq-CLF bind- 
ing to monocytes by 61% and 77% alone, and 55% and 
820/o, respectively, in the presence of l-10 mglml man- 
nan. These data suggest that the inhibition is not due to 
lectin,interaction of MBP with the cell surface or the recep- 
Table 1. MBP Enhances CR1 -Mediated Phagocytosis 
Experiment 
Uncoated Albumin” c1q 
number PercenF I Percent I Percent I Percent I 
1 7.5 f 2 12 2 6 451 5*3 26.5 f 9 45.5 + 20 50 * 1 116 k 0 
2 9.4 + 4 19 f 11 74.5 f 6 262 + 31 62.5 f 7 214 f 30 
3 25 + 6.6 45 * 16 46 f 0 65 + 0.7 46 k 12 100 * 36 
4 6k4 6.5 + 9 49 t 4 103 + 35 60 + 9 130 f 40 
a HSA in experiments 1 and 4; BSA in experiment 3. 
’ Coating concentration for all proteins was 8 uglml, except for MBP in experiment 3, in which the coating concentration was 10 @ml. 
c Percentage of cells ingesting targets; I, phagocytic index; number of targets ingested per 100 cells counted. 
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Figure 2. Anti-C1qRp Inhibits Map-Enhanced Phagocytosis 
Human monocytes were preincubated with buffer (closed bars), R139 
(anti-Clq&) (hatched bars), or control mouse IgG ((open bars) prior 
to addition to wells precoated with 4 uglml HSA, Clq, rMBP, or fibro- 
nectin. After 1 hr adherence, EAC4b targets were added along with 
10 nglml PDBu and phagocytosis assessed. The error bars represent 
the standard deviation of duplicate samples from a single experiment. 
Results are from one experiment representative of a total of three such 
experiments, with different donors, R139 antibody preparations, and 
ligand preparations. 
tor, but rather that a common interaction domain exists 
within the collagen-like region of these molecules. In addi- 
tion, the fact that only partial inhibition of Cl q binding was 
demonstrated supports the hypothesis that there is more 
than one binding site for Clq-CLF on these cell types, and 
that MBP may provide a mechanism for distinguishing the 
various Clq binding sites/receptor types. 
Discussion 
The data in this paper demonstrate that MBP can interact 
with the mononuclear phagocyte cell surface to enhance 
phagocytosis. In addition, a MAb that recognizes a 126,000 
M, cell surface protein and that previously has been shown 
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Figure 3. Effect of MBP on Clq Binding to Monocytes 
1251-Clq-CLF was added to human monocytes in the presence of in- 
creasing concentrations of rMBP, unlabeled Clq, or unlabeled Clq 
CLF. After incubation on ice for 30 min, the cells were spun through 
phthalate cushion and cell-associated radiolabel was determined. The 
percent of control binding in the presence of MBP (closed circle) 
(n = 4, three separate experiments), unlabeled Clq (closed triangle) 
(n = I), or unlabeled Clq-CLF (closed square) (n = 2). Error bars 
depict standard deviation of the mean. In each individual experiment, 
samples were run in triplicate or duplicate. Total counts bound in the 
control, uncompeted samples were 1622-l 1943 cpm depending on 
the specific activity of the labeled protein. 
to inhibit specifically the Cl q-mediated enhancement of 
phagocytosis, also inhibits the MBP-induced increase in 
monocyte phagocytic capacity. Thus, the receptor(s) for 
these two macromolecules that mediate the enhancement 
of phagocytosis share at least one critical surface polypep- 
tide component. As is becoming increasing evident in 
many ligandlreceptor systems, receptors are often multi- 
subunit complexes, containing ligand binding compo- 
nents as well as polypeptides that are involved in the sig- 
naling function of the receptor. Whether the component of 
the phagocytosis modulating receptor (Cl qRp) recognized 
by the MAb, R139, is the ligand binding component of 
the receptor(s) or has another role in receptor signaling 
remains to be seen. 
Soell and colleagues (1995) recently showed that MBP- 
containing complexes are ingested by human monocytes. 
The data presented here differ from that report in that 
here MBP is not associated or bound to the target being 
ingested. Rather, cell interaction with MBP alone induces 
as yet unknown intracellular responses, such that upon 
binding of a target to a separate recognition receptor, such 
as FcR or CR 1, phagocytosis occurs in a larger percentage 
of the myeloid cell population, with each cell ingesting 
more targets within a given time period. Levitz et al. (1993) 
recently reported that monocytes and PMN cultured on 
immobilized MBP demonstrated increased binding to 
Cryptococcus neoformans. It will be interesting to deter- 
mine whether this “activation” receptor is also involved in 
the cell interaction that mediates the enhanced binding, 
ingestion, or both of MBP-coated particles. 
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Figure 4. Effect of MBP on Clq Binding to Neutrophils 
The percent of control binding is the mean percent control binding 
calculated from three experiments for rMBP (closed circle) (performed 
in triplicate or duplicate). In one of the experiments, unlabeled Clq- 
CLF was added in increasing concentrations (closed square), whereas 
intwootherexperimentsClqwasaddedasthecontro1 inhibitor(closed 
triangle). Error bars depict standard deviation of the mean. The aver- 
age maximal binding in each experiment varied from 1952-9623 cpm, 
correlating with the specific activity of the Clq-CLF. 
Previously reported experiments have demonstrated 
that the Clq cell interaction site that mediates enhanced 
phagocytic capacity is located on the collagen-like portion 
of the Clq molecule (Tenner and Cooper, 1980; Bobak 
et al., 1987) and that SP-A enhances FcR- and CRl- 
mediated phagocytosis in human monocytes and macro- 
phages (Tenner et al., 1989) and serum-opsonized bacte- 
ria by rat alveolar macrophages (van lwaarden et al., 
1990). These data are consistent with the hypothesis that 
it is the common collagen-like structure of these molecules 
that mediates this cell activation. (The globular domains 
of SP-A and MBP share some homology with each other 
[Ca’+ and carbohydrate binding domains] but not with 
Clq.) Collagen type IV (Brown and Goodwin, 1988) has 
also been shown to increase phagocytic capacity of mono- 
cytes, while collagen type I does not (Bobak et al., 1987) 
indicating that there is some specificity within the collagen- 
containing molecules that is critical for recognition by the 
cellular receptor(s) that mediate this enhancement of 
phagocytic function. The ability of MBP to inhibit a portion 
of the binding of Clq-CLF to these cells suggests that 
MBP and Clq do interact with a common surface binding 
site. These observations are consistent with the findings 
of Soell and colleagues that soluble Clq inhibited the bind- 
ing of MBP-containing complexes to human monocytes 
(Soell et al., 1995). The degree of inhibition was not in- 
fluenced by interactions of the carbohydrate recognition 
domain of MBP with either the monocyte cell surface or 
Clq, as mannan (which effectively saturates the lectin 
binding site of MBP) did not effect the percent inhibition 
of 1251-C1q-CLF by MBP. Since the lectin binding specific- 
ity of MBP, verified by definition of the structure of the 
cocrystals of MBP and its ligand (Weis et al., 1992), is 
such that it recognizes microbial carbohydrate structures 
and not mammalian oligosaccharides, this result was not 
unexpected. While these data suggest a common cell in- 
teraction motif on the ligands, further evidence is neces- 
sary to show that the receptor(s) that modulate(s) phagocy- 
tosis are completely identical, as multiple receptors for 
these large ligands may exist regulating different cellular 
responses. 
The binding data presented here also suggest that there 
is more than one binding site/receptor for Clq on mono- 
cytes, PMN, and U937, since MBP inhibits only a portion 
of Clq-CLF binding to each of these cell types. This is 
consistent with the biochemical isolation of different Clq 
binding proteins from a variety of cells and the differential 
sensitivity of Cl q-mediated cellular functions to regulation 
by MAbs. In addition to the 126,000 M, protein demon- 
strated to be a component of the Clq receptor that me- 
diates the Clq enhancement of phagocytosis (ClqRp) 
(Guan et al., 1991) a Clq binding protein with different 
apparent molecular weight (in the 56,000 M, range) has 
been purified by several laboratories (Ghebrehiwet et al., 
1992; Peerschke and Ghebrehiwet, 1988; Malhotra et al., 
1988). This latter protein has been reported to have se- 
quence similarity to calreticulin (Malhotra et al., 1993), and 
in solid phase in vitro assays this protein binds multiple 
members of the collectin family (Malhotra et al., 1990). 
Polyclonal antibodies to the calreticulin-like collectin bind- 
ing protein inhibit adhesion of fibroblasts (Bordin et al., 
1990) and platelets (Peerschke and Ghebrehiwet, 1990) 
to Clq-coated surfaces, suggesting a role for this protein 
in ligand-cell interactions. In contrast, two MAbs to the 
126,000 M, ClqR, have been shown to inhibit Clq- 
mediated monocyte function (Guan et al., 1991, 1994) 
but not Clq-mediated 02- production by PMN (Guan et 
al., 1994). Furthermore, unlike Clq, neither SP-A nor MBP 
immobilized to plastic surfaces trigger 02- production 
(Goodman and Tenner, 1992) again suggesting that the 
Clq receptors that mediate these different effects are not 
identical. Alternatively, this lack of an effect on neutrophil 
function by MBP and SP-A may be due to an inappropriate 
presentation of the molecules, as Kuhlman et al. (1989) 
have shown the enhancement of neutrophil 02- production 
when Salmonella are preopsonized with MBP prior to addi- 
tion to PMN. This type of “receptor diversity” is similar to 
the well-established demonstration of multiple classes of 
Fc and C3 receptors on these cells, which mediate differ- 
ent functions. This receptor diversity ultimately should be 
useful in modulating these activities therapeutically. 
Clq is normally present in blood in complex with 
ClrZClsn, such that the receptor interaction site of Clq 
is masked. Upon binding of Clq in Cl to an activating 
substance such as an immune complex, bacteria, or other 
pathogen, the proenzymes Cl r and Cls are activated and 
become susceptible to inactivation by the serum regula- 
tory protein, Cl inhibitor. This inhibitor forms a covalent 
complex with activated Cl r and activated Cl s, abrogating 
enzymatic activity and resulting in the dissociation of acti- 
vated Cl r2C1s2 from Clq (reviewed by Cooper, 1985). It 
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is that region of the collagen-like domain that becomes 
exposed as a result of this dissociation of activated Cl r&l sZ, 
which interacts with specific cell surface receptors (Tenner 
and Cooper, 1980; Bobak et al., 1987) leading to the modu- 
lation of cell function. Thus, in addition to its role as the 
recognition subunit of the first component of the classical 
complement cascade, Clq may provide a direct means 
of triggering or enhancing host defense responses during 
early stages of disease or infection when antibody or cellu- 
lar defense mechanisms have not yet developed (Cooper, 
1985). As mentioned above, SP-A and MBP have also 
been shown to enhance the uptake of specific classes of 
molecules (Tenner et al., 1989; Drickamer et al., 1986; 
Ezekowitz et al., 1988; Voss et al., 1988; White et al., 
1985). Since the globular regions of SP-A and MBP have 
lectin-like properties, which confer a specificity of binding 
to that region of the molecule, it has recently been sug- 
gested that these lectins and other proteins containing 
collagen-like sequences (including Clq) may have evolved 
prior to IgG as defense recognition molecules and that 
these molecules also may play an important role at early 
stages of disease and in other conditions where ample 
antibodies may not present (for example, prior to genera- 
tion of anti-carbohydrate IgG in young children [Ezekowitz, 
1991; Farries et al., 1990; Thiel and Reid, 1989)). 
Phagocytosis is a major host defense mechanism by 
which potentially deleterious material is removed and 
made accessible to inactivation. The phagocytic capacity/ 
potential of a cell can be modulated by cytokines that trig- 
ger cellular differentiation (Gresham et al., 1986; Sampson 
et al., 1991) or by other activation ligands, which enhance 
the phagocytic response of the cell upon interaction of a 
separate (opsonic) ligand with its cell surface receptors 
(reviewed by Brown, 1986). This activation is probably rele- 
vant at sites of inflammation where cytokines, MBP, Clq, 
or other regulatory molecules may accumulate and en- 
hance the phagocytic capacity of acute inflammatory cells. 
The molecular events involved in the phagocytic process 
and in its regulation have not been completely elucidated, 
although it is clear that more than one pathway can be 
evoked (Gresham et al., 1988,1989; Brown, 1986; Brown 
and Goodwin, 1988; Pommier et al., 1984, 1983). For ex- 
ample, a MAb (B6H12) directed against an integrin- 
associated protein (Brown et al., 1990) has been shown to 
block the enhancement of phagocytosis induced by many, 
but not all, RGD containing extracellular matrix proteins 
(Gresham et al., 1989). That MAb (B6H12) does not block 
the Cl q mediated enhancement of phagocytosis, whereas 
the antibody to ClqRp inhibits Clq- and MBP-mediated, 
but not fibronectin-mediated, enhancement of phagocyto- 
sis (Guan et al., 1991). Future studies should elucidate 
further common molecular features of the receptor com- 
plexes or the signal transduction pathways for the mole- 
cules that share a similar collagen-like domain, thereby 
determining whether or not the previously described “Clq” 
receptor that mediates the enhancement of phagocytosis 
(Guan et al., 1991) is a receptor that binds multiple ligands 
to trigger the enhancement of cell function or whether the 
similarity of receptors involves only the 126,000 M, sub- 
unit. In addition to advancing the general understanding of 
the regulation of host phagocytic function, such receptor- 
receptor systems may be amenable to common beneficial 
manipulation. 
Experimental Procedures 
Media, Reagents, and Antibodies 
RPM1 1640 medium was either purchased from GIBCO (Long Island, 
New York) or from the production laboratory of the American Red 
Cross (Rockviile, Maryland). HLl medium was purchased from Ven- 
trex Laboratories(Portland, Maine). FCS andsupplementedcalf serum 
(SCS) were purchased from Hyclone (Logan, Utah). L-glutamine and 
gentamicin were obtained from M. A. Bioproducts (Waikersville, Mary- 
land). Sheep erythrocytes are purchased from Colorado Serum (Den- 
ver, Colorado). Anti-sheep red blood cells, both IgG and IgM, were 
purchased from Diamedix (Miami, Florida). The human serum albumin 
used for the elutriation buffer obtained from the American Red Cross 
was prepared by Travenol Laboratories, Incorporated (Glendale, Caii- 
fornia). All other reagents used, except where noted otherwise, were 
obtained in the highest quality available from Sigma Chemical Com- 
pany (St. Louis, Missouri). The MAb, R139, that recognizes a cell 
surface protein (100,000 M, nonreduced, 126,000 M, reduced), was 
derived after immunization with partially purified Clq-binding proteins, 
obtained from affinity purification on Clq-CLF-Sepharose as pre- 
viously reported (Guan et al., 1991). 
Protein Isolation and lodination 
MBP was isolated from serum or recombinant MBP (rMBP) prepared 
as previously described (Ezekowitz et al., 1969 and Super et al., 1992, 
respectively). Clq was isolated from plasma-derived human serum by 
the method of Tenner et al. (1961), modified as described (Young et 
al., 1991). The preparations used were fully active as determined by 
hemolytic titration and homogeneous as assessed by sodium dodecyl 
sulfate-poiyacrimide gel electrophoresis. Cl q collagen-like fragments 
(Clq-CLF) were obtained by the digestion of Clq with pepsin using 
the procedure of Reid (1976) as modified by Siegel and Schumaker 
(1963). Protein concentration was determined using an extinction coef- 
ficient (El”) at 260 nm of 6.62 for Clq (Reid et al., 1972) and 2.1 for 
Clq-CLF (Siegel and Schumaker, 1963). The iodogen method (Pierce, 
Rockford, Illinois) has been determined to be optimal for radiolabeling 
the Clq-CLF (Guan et al., 1991). The specific activity of the ‘=I-Clq- 
CLF was approximately 0.7-1.5 pC/Ng. All proteins were stored 
at -70%. Purified human fibronectin was provided by Drs. S. Huff 
and K. lngham (American Red Cross Holland Laboratory, Rockville, 
Maryland). 
Cells 
For experiments investigating the enhancement of phagocytosis and 
binding of ligands to monocytes, human peripheral blood monocytes 
were isolated by counterflow elutriation using a modification of the 
technique of Lionetti et al. (1980) as described (Bobak et al., 1986). 
Blood units were collected into CPDAl by the Washington D. C. Re- 
gional Blood Service of the American Red Cross or by the University 
of California at Irvine Medical Center Blood Bank (Orange, California) 
or at the University of California at Irvine Medical Plaza, Irvine, Califor- 
nia. Greater than 92% of the cells in each preparation were monocytes, 
according to size analysis on a Coulter Channelyzer. Macrophages 
in these experimentswere elutriated monocytes that had been cultured 
in Teflon jars (Savillex Corporation, Minnetonka, Minnesota) at 1 x 
lo6 cells/ml in HL-1 culture medium (a serum-free defined medium) 
as previously reported (Tenner et al., 1969) or in FCS. On days 2-6 
of culture, macrophages were collected and washed three times in 
phosphate-buffered saline (PBS) before use. Only cultures containing 
>90% viable cells as assessed by trypan blue exclusion were used. 
As previously published, the number of cells adhered to the LabTek 
chamber slides coated with various proteins did not differ significantly 
(Bobak et al., 1987). 
Phagocytosis Assay 
Sheep erythrocytes bearing IgG anti-sheep red blood cells (EA& or 
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IgM anti-Forssman antibody and C4b (EAC4b) were prepared as pre- 
viously described (Bohnsack et al., 1985). Phagocytosiswas assessed 
as previously described (Bobak et al., 1988; Bohnsack et al., 1985). 
In brief, a-well LabTek chambers were coated with varying concentra- 
tions of Clq, MBP. fibronectin, or BSA or HSA (Bobak et al., 1988). 
Monocytes or macrophages (6.25 x lO’cells/well) are added to each 
chamber, and the cells allowed to adhere for 1 hr at 37% in 5% COI. 
Targets were then added (lO’/lOO ul) and incubated for 30 min at 
37°C. After removing E that were not cell-associated by washing, non- 
ingested E were removed by hypotonic lysis. After fixation in 1% glutar- 
aldehyde and staining with Giemsa, phagocytosis was quantitated 
using light microscopy. In experiments in which monocytes, or mono- 
cytescultured in HL-1, wereassessedforCRl-mediatedphagocytosis, 
10 nglml PDBu was added with the opsonized targets, as it is well 
known that while monocytes can bind to targets via CRI, this receptor 
must be “activated” to mediate phagocytosis in these less differenti- 
ated cells. The pretreatment of monocytes or HL-l-derived macro- 
phages with phorbol esters such as PDBu (which is not necessary for 
the more activated serum-cultured macrophages) enables phagocyto- 
sis of complement-opsonized targets as previously elaborated (Bobak 
et al., 1988). The number of E targets ingested per 100 effector cells 
was defined as the phagocytic index, whereas the percentage of ef- 
fector cells ingesting at least one E target was defined as the percent 
phagocytosis. Each experiment, performed on separate days with dif- 
ferent donors, used duplicate sample wells per condition. Controls of 
unopsonized E, E opsonized with IgM anti-Forssman alone (E-IgM), 
or both were not ingested by monocytes or macrophages under any 
conditions. In some experiments, monocytes (5 x 105/ml) were pre- 
treated for 15 min at room temperature with 6-20 ug/ml RI 39 (a mouse 
IgGPb monoclonal anti-ClqRp [Guan et al., 19911) or control mouse 
monoclonal IgGPb prior to a 2-fold dilution and addition to chambers 
as above. 
Clq Binding Assays 
It has been previously established that Clq-CLF contains the func- 
tional cell binding domain. Therefore, all assays of Clq binding to 
cells (5 x 105-1 x 106cells/sample) were performed with the iodinated 
Clq collagen-like fragment (< or = 0.2 ag ‘251-C1q-CLF/sample). The 
incubations were carried out in 60% RPMI, 0.02 M HEPES, 1% oval- 
bumin, 40% sucrose, 0.02M HEPES, 1% ovalbumin (p = 0.09) as 
previously described (Tenner and Cooper, 1980). All other aspects of 
the assay were also as previously described (Tenner and Cooper, 
1980; Bobak et al., 1986). Assays are usually done in triplicate, except 
where noted in the figure legends. In all experiments, the total number 
of counts bound represented less than 6.5% of the total input radiola- 
bel. Statistical analysis was performed using the student’s t test. 
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